Brainomix Completes $18M Series C Investment Round for AI-Powered Imaging Tools

Brainomix, a company specializing in AI-powered imaging tools for stroke and lung fibrosis, has recently closed a £14M ($18M) Series C investment round. The funding round was led by prominent healthtech investors including Parkwalk Advisors, the UK's largest growth EIS fund manager, the Boehringer Ingelheim Venture Fund (BIVF), and Hostplus via the IP Group Hostplus Innovation Fund.

Brainomix, a spinout from the University of Oxford, operates globally and has developed an AI platform, Brainomix 360 Stroke, to automate imaging biomarkers for better diagnosis and treatment decisions. With the completion of this investment round, the company plans to expand its commercial operations in the US and enhance its AI-powered technology portfolio to facilitate quicker diagnosis and improve access to life-saving treatments.

Additionally, the funding will support the company's expansion of its Oxford-based operations and global commercial team. In addition to its focus on stroke, Brainomix has applied its AI expertise to lung fibrosis, developing the Brainomix 360 e-Lung technology to predict disease progression accurately. The company has also partnered with Boehringer Ingelheim to evaluate the real-world impact of e-Lung. The company's achievements and potential were also acknowledged by Parkwalk and Boehringer Ingelheim Venture Fund, with both expressing excitement and optimism about Brainomix's impact on healthcare.

 Brainomix specializes in AI-powered software solutions for precision medicine, with its first product, the Brainomix 360 stroke platform, being clinically adopted in hundreds of hospitals worldwide. The company's technology aims to drive increased treatment rates and improve functional independence for patients. For more information about Brainomix and its technology, visit www.brainomix.com.

Learn more about the funding here.